Top Story

FDA grants orphan drug status to ovarian cancer treatment

January 26, 2015

The FDA granted orphan drug designation to liposomal encapsulated paclitaxel, or LEP-ETU, an ovarian cancer treatment in development by Insys Therapeutics Inc., the company announced today.

“We are pleased to have received orphan drug designation for LEP-ETU to treat ovarian cancer, a devastating and difficult-to-treat disease,” Michael L. Babich, president and CEO of Insys Therapeutics, said in a press release. “By entrapping the paclitaxel with liposomes, we believe our LEP-ETU formulation could potentially have reduced toxicity, while maintaining or enhancing efficacy of the cancer-fighting paclitaxel. We are currently evaluating next steps with respect to this drug product candidate.”

In the Journals

Majority of PCPs assigned high value to medical imaging

January 26, 2015
The majority of primary care physicians considered access to medical imaging to be essential to patient care, indicating that it aided in establishing earlier and more…
In the Journals

'Lack of understanding' about disease common in women with breast cancer

January 26, 2015
Many women with breast cancer possessed a poor understanding of their tumors and disease characteristics, according to study results.These knowledge deficiencies were…
Debasish Tripathy CommentaryMeeting News CoveragePublication Exclusive

Immunotherapy trials shift breast cancer research closer to ‘Holy Grail’

HemOnc Today, January 25, 2015
Debu Tripathy, MD
Immunotherapy is an area that has been a Holy Grail, if you will, in the field of breast cancer.We have long wondered whether the immune system could be harnessed to…
Daniel Hayes Association News

ASCO elects 2016 president

January 24, 2015
Daniel F. Hayes, MD, FASCO, will serve as president of ASCO for the term beginning in June 2016.He will become president-elect during the society’s annual meeting…
More News Headlines »
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
morganatic-roan morganatic-roan